Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 1/20 | 0.38 |
| ▸ | ELANE | P08246 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15663066 | 0.82 | FAAH (0.33) | FAAH | |
| SCHEMBL26712709 | 0.77 | FAAH (0.38) | FAAHELANEUSP2SMN1; SMN2 | |
| SCHEMBL3086177 | 0.77 | FAAH (0.40) | FAAHELANEUSP2SMN1; SMN2 | |
| SCHEMBL10236319 | 0.77 | FAAH (0.40) | FAAHELANEUSP2SMN1; SMN2 | |
| SCHEMBL3231153 | 0.77 | ALDH1A1 (0.47) | FAAHELANE | |
| SCHEMBL28915641 | 0.74 | FAAH (0.41) | FAAHELANEUSP2SMN1; SMN2 | |
| SCHEMBL6963629 | 0.74 | FAAH (0.38) | FAAHELANEUSP2SMN1; SMN2 | |
| SCHEMBL10279632 | 0.74 | FAAH (0.41) | FAAHELANEUSP2SMN1; SMN2 | |
| SCHEMBL6956991 | 0.73 | CYP1A2 (0.43) | FAAHELANE | |
| SCHEMBL22122136 | 0.73 | NR3C1 (0.45) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260069605-A1 | KRAS INHIBITORS | INCYTE CORP (US) | 2026-03-12 | — | — | US | disclosed |
| US-20250346616-A1 | ROCK INHIBITORS AND USES THEREOF | DIZAL JIANGSU PHARMACEUTICAL CO LTD (CN) | 2025-11-13 | — | — | US | disclosed |
| WO-2025096706-A1 | MODULATORS OF BCL6 AS LIGAND DIRECTED DEGRADERS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-05-08 | — | — | WO | disclosed |
| WO-2025096771-A1 | MODULATORS OF BCL6 AS LIGAND DIRECTED DEGRADERS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-05-08 | — | — | WO | disclosed |
| EP-4532484-A1 | ROCK INHIBITORS AND USES THEREOF | DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) | 2025-04-09 | — | — | EP | disclosed |
| CN-119173509-A | ROCK inhibitors and uses thereof | 迪哲(江苏)医药股份有限公司 | 2024-12-20 | — | — | CN | disclosed |
| US-20240190860-A1 | 8-CYCLO-SUBSTITUTED QUINAZOLINE DERIVATIVES AS LPA RECEPTOR 2 INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2024-06-13 | — | — | US | disclosed |
| CN-114901646-B | Benzotriazine bisoxides and pharmaceutical compositions thereof | 浙江瑞臻医药有限公司 | 2024-06-04 | — | — | CN | disclosed |
| EP-4313956-A1 | 8-CYCLO-SUBSTITUTED QUINAZOLINE DERIVATIVES AS LPA RECEPTOR 2 INHIBITORS | Chiesi Farmaceutici S.p.A. (IT) | 2024-02-07 | — | — | EP | disclosed |
| WO-2023226965-A1 | ROCK INHIBITORS AND USES THEREOF | DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) | 2023-11-30 | — | — | WO | disclosed |
| WO-2023019912-A1 | BENZOTRIAZINE DIOXIDE AND PHARMACEUTICAL COMPOSITION THEREOF | 杭州瑞臻医药有限公司 | 2023-02-23 | — | — | WO | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| CN-114901646-A | Benzotriazine double oxide and pharmaceutical composition thereof | 杭州瑞臻医药有限公司 | 2022-08-12 | — | — | CN | disclosed |
| US-20210147398-A1 | NOVEL LXR MODULATORS WITH BICYCLIC CORE MOIETY | PHENEX-FXR GMBH (DE) | 2021-05-20 | — | — | US | disclosed |
| US-9364466-B2 | Heterocyclic compounds as protein kinase inhibitors | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2016-06-14 | — | — | US | disclosed |
| EP-2714688-B1 | HETEROCYCLIC COMPOUNDS AS PROTEIN KINASE INHIBITORS | DAIICHI SANKYO CO LTD (JP) | 2016-02-24 | — | — | EP | disclosed |
| US-20150157613-A1 | HETEROCYCLIC COMPOUNDS AS PROTEIN KINASE INHIBITORS | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2015-06-11 | — | — | US | disclosed |
| US-8980911-B2 | Heterocyclic compounds as protein kinase inhibitors | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2015-03-17 | — | — | US | disclosed |
| US-20140155398-A1 | HETEROCYCLIC COMPOUNDS AS PROTEIN KINASE INHIBITORS | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2014-06-05 | — | — | US | disclosed |
| WO-2012160464-A1 | HETEROCYCLIC COMPOUNDS AS PROTEIN KINASE INHIBITORS | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250346616-A1 | ROCK INHIBITORS AND USES THEREOF | ROCK1, ROCK2, RHOA | FAAH 3158/4885ELANE 3275/4885USP2 3453/4885 |
| US-20150157613-A1 | HETEROCYCLIC COMPOUNDS AS PROTEIN KINASE INHIBITORS | MAP3K1, JAK2, AKT1 | FAAH 1200/4885ELANE 3435/4885USP2 2635/4885 |
| US-20240190860-A1 | 8-CYCLO-SUBSTITUTED QUINAZOLINE DERIVATIVES AS LPA RECEPTOR 2 INHIBITORS | LPAR2, LPAR5, LPAR1 | FAAH 346/4885ELANE 733/4885USP2 1813/4885 |
| US-20210147398-A1 | NOVEL LXR MODULATORS WITH BICYCLIC CORE MOIETY | NR1H2, NR1H3, NR1H4 | FAAH 858/4885ELANE 4037/4885USP2 3225/4885 |
| US-20260069605-A1 | KRAS INHIBITORS | KRAS, NRAS, HRAS | FAAH 2905/4885ELANE 1756/4885USP2 3609/4885 |
| US-20140155398-A1 | HETEROCYCLIC COMPOUNDS AS PROTEIN KINASE INHIBITORS | MAP3K1, JAK2, AKT1 | FAAH 1200/4885ELANE 3435/4885USP2 2635/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.